GlassScriptPhysician profile
Ronald M Lahasky
NPI 1487768214
$10,475.43
in general payments reported to CMS, 2019-2025
48 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,351 · 2021: $1,515 · 2022: $1,540 · 2023: $1,502 · 2024: $1,198 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,042.41 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $725.86 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $639.98 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $619.14 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $568.18 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $554.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $550.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $541.72 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $489.19 | 2019-2022 | |
| Abbvie INC. | $440.80 | 2021-2025 | |
| Allergan, INC. | $315.08 | 2019-2020 | |
| Exact Sciences Corporation | $311.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $296.46 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.20 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $268.75 | 2023-2025 | Rexulti, Nuedexta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Lahasky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.